161 related articles for article (PubMed ID: 29510814)
1. von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome.
Binderup MLM
Dan Med J; 2018 Mar; 65(3):. PubMed ID: 29510814
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark.
Binderup ML; Galanakis M; Budtz-Jørgensen E; Kosteljanetz M; Luise Bisgaard M
Eur J Hum Genet; 2017 Feb; 25(3):301-307. PubMed ID: 27966541
[TBL] [Abstract][Full Text] [Related]
3. Risk of new tumors in von Hippel-Lindau patients depends on age and genotype.
Binderup ML; Budtz-Jørgensen E; Bisgaard ML
Genet Med; 2016 Jan; 18(1):89-97. PubMed ID: 25834951
[TBL] [Abstract][Full Text] [Related]
4. Survival and causes of death in patients with von Hippel-Lindau disease.
Binderup ML; Jensen AM; Budtz-Jørgensen E; Bisgaard ML
J Med Genet; 2017 Jan; 54(1):11-18. PubMed ID: 27539272
[TBL] [Abstract][Full Text] [Related]
5. Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition.
Binderup ML; Bisgaard ML; Harbud V; Møller HU; Gimsing S; Friis-Hansen L; Hansen Tv; Bagi P; Knigge U; Kosteljanetz M; Bøgeskov L; Thomsen C; Gerdes AM; Ousager LB; Sunde L;
Dan Med J; 2013 Dec; 60(12):B4763. PubMed ID: 24355456
[TBL] [Abstract][Full Text] [Related]
6. New von Hippel-Lindau manifestations develop at the same or decreased rates in pregnancy.
Binderup ML; Budtz-Jørgensen E; Bisgaard ML
Neurology; 2015 Oct; 85(17):1500-3. PubMed ID: 26408493
[TBL] [Abstract][Full Text] [Related]
7. A genetic register for von Hippel-Lindau disease.
Maddock IR; Moran A; Maher ER; Teare MD; Norman A; Payne SJ; Whitehouse R; Dodd C; Lavin M; Hartley N; Super M; Evans DG
J Med Genet; 1996 Feb; 33(2):120-7. PubMed ID: 8929948
[TBL] [Abstract][Full Text] [Related]
8. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease.
Binderup MLM; Stendell AS; Galanakis M; Møller HU; Kiilgaard JF; Bisgaard ML
Br J Ophthalmol; 2018 Jul; 102(7):942-947. PubMed ID: 28972023
[TBL] [Abstract][Full Text] [Related]
9. Surveillance in von Hippel-Lindau disease (vHL).
Poulsen ML; Budtz-Jørgensen E; Bisgaard ML
Clin Genet; 2010 Jan; 77(1):49-59. PubMed ID: 19863552
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for survival in patients with von Hippel-Lindau disease.
Wang JY; Peng SH; Li T; Ning XH; Liu SJ; Hong BA; Liu JY; Wu PJ; Zhou BW; Zhou JC; Qi NN; Peng X; Zhang JF; Ma KF; Cai L; Gong K
J Med Genet; 2018 May; 55(5):322-328. PubMed ID: 29330336
[TBL] [Abstract][Full Text] [Related]
11. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.
Mettu P; Agrón E; Samtani S; Chew EY; Wong WT
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4464-70. PubMed ID: 20375333
[TBL] [Abstract][Full Text] [Related]
13. Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations.
Kruizinga RC; Sluiter WJ; de Vries EG; Zonnenberg BA; Lips CJ; van der Horst-Schrivers AN; Walenkamp AM; Links TP
Endocr Relat Cancer; 2014 Feb; 21(1):63-71. PubMed ID: 24132471
[TBL] [Abstract][Full Text] [Related]
14. Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families.
Vikkath N; Valiyaveedan S; Nampoothiri S; Radhakrishnan N; Pillai GS; Nair V; Pooleri GK; Mathew G; Menon KN; Ariyannur PS; Pillai AB
Fam Cancer; 2015 Dec; 14(4):585-94. PubMed ID: 25952756
[TBL] [Abstract][Full Text] [Related]
15. Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease.
Rasmussen A; Alonso E; Ochoa A; De Biase I; Familiar I; Yescas P; Sosa AL; Rodríguez Y; Chávez M; López-López M; Bidichandani SI
BMC Med Genet; 2010 Jan; 11():4. PubMed ID: 20064270
[TBL] [Abstract][Full Text] [Related]
16. VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortality.
Bender BU; Eng C; Olschewski M; Berger DP; Laubenberger J; Altehöfer C; Kirste G; Orszagh M; van Velthoven V; Miosczka H; Schmidt D; Neumann HP
J Med Genet; 2001 Aug; 38(8):508-14. PubMed ID: 11483638
[TBL] [Abstract][Full Text] [Related]
17. The incidence of consecutive manifestations in Von Hippel-Lindau disease.
van der Horst-Schrivers ANA; Sluiter WJ; Kruizinga RC; van Leeuwaarde RS; Giles R; Olderode-Berends MJW; Links TP
Fam Cancer; 2019 Jul; 18(3):369-376. PubMed ID: 31087189
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau development in children and adolescents.
Launbjerg K; Bache I; Galanakis M; Bisgaard ML; Binderup MLM
Am J Med Genet A; 2017 Sep; 173(9):2381-2394. PubMed ID: 28650583
[TBL] [Abstract][Full Text] [Related]
20. Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study.
Xie H; Ma K; Zhang J; Hong B; Zhou J; Li L; Zhang K; Gong K; Cai L
J Med Genet; 2020 Nov; 57(11):744-751. PubMed ID: 32303605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
